Indolent B-cell Lymphoma Completed Phase 0 Trials for Decitabine (DB01262)

IndicationStatusPhase
DBCOND0043724 (Indolent B-cell Lymphoma)Completed0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02846935p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid MalignanciesTreatment